PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/
Follow Project-Comfort LinkedIn Page: https://www.linkedin.com/company/project-comfort (Graphic: Business Wire)
“We are proud to collaborate on this groundbreaking project, which perfectly aligns with our commitment to advancing healthcare solutions that prioritize patients,” said Luca Zanotti Fragonara, Advanced Technologies Competence Center Lead at PQE Group. “Together with our partners, we aim to make blood collection and diagnostics more accessible, comfortable, and efficient, ultimately improving health outcomes globally.”
On behalf of the consortium, Project Leader Antoniu L. Fantana, PhD, Sr. Director, Eli Lilly and Company stated: “Our goal is to redefine diagnostics by placing patient needs at the forefront and expanding healthcare access globally. Together with 51 dedicated organizations, we are committed to establishing a new standard in blood collection and diagnostics that combines patient comfort and accessibility with higher quality data.”
Traditional blood collection methods, such as venipuncture, can be burdensome and uncomfortable, particularly for patients with limited mobility, children, the elderly, and those in rural or underserved areas. The need to visit a clinical setting often poses additional challenges, including time, cost, and travel barriers. Project-COMFORT addresses these obstacles head-on by advancing Patient-Centric Microsampling — an approach allowing smaller blood samples to be collected comfortably at home or in other convenient locations. This shift will greatly enhance diagnostic accessibility, reduce patient discomfort, and make timely health monitoring a reality for those who need it most.
“By offering a minimally invasive, patient-friendly alternative, microsampling represents a major step forward in democratizing healthcare access,” noted Scientific Coordinator Chi Pakarinen. “Our project is about breaking down barriers to care and reimagining blood diagnostics as an inclusive, adaptable service that meets patients where they are.”
Project-COMFORT leverages the diverse expertise of its partners, blending insights from healthcare providers, research institutions, patient advocacy groups, and technology innovators. The aim is to also involve regulatory and HTA experts from the start to ensure the best chances for successful project implementation and better uptake of project results. This unique collaboration integrates advanced clinical research, regulatory compliance, and technological development, creating a robust foundation for microsampling to emerge as a recognized standard. With expertise spanning a broad array of disciplines, the consortium partners are collectively building a model that can lead to more patient-centered, efficient healthcare in the future.
“At the heart of Project-COMFORT is a commitment to patient-centered innovation,” said Administrative Coordinator Professor Georgios Theodoridis, School of Chemistry, Aristotle University of Thessaloniki. “This project holds groundbreaking potential to make Patient-Centric Microsampling an accepted alternative to traditional blood draws, fundamentally transforming the diagnostic experience for patients. By reducing the burden of testing and enhancing accessibility, we are paving the way for data-driven healthcare advancements that will improve patient outcomes and support more effective healthcare planning worldwide.”
The project’s ultimate goal is to generate impactful, data-driven insights that not only improve individual patient care but also guide public health strategies. The rich data made available through microsampling technology has the potential to influence healthcare policy, resource allocation, and preventive care measures, leading to a healthier, more resilient population.
With this launch, Project-COMFORT embarks on a journey of global impact, backed by €6,6 million in funding and an unparalleled commitment from its diverse network of partners. By engaging patient communities, healthcare providers, and regulatory bodies from the outset, the project will ensure that each stage of development is attuned to real-world needs and expectations. As Project-COMFORT progresses, regular updates and collaboration opportunities will be shared to welcome stakeholders into this groundbreaking healthcare transformation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241229266268/en/
Contacts
Media Contact:
Michela Lijoi – m.lijoi@pqegroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Computershare Acquires CMi2i2.1.2025 13:09:00 EET | Press release
Computershare Limited (ASX: CPU) has announced that it has acquired CMi2i Limited. CMi2i provides independent and trusted advice to boards, executives and advisors of some of the largest public companies around the world. The company’s investor intelligence services, including its bondholder offering, help companies to identify and engage with investors on complex, contested and high stakes issues. It employs around 20 people in London and has a presence in New York, Milan and Madrid. Fiona Chalmers, CEO Issuer Services at Computershare said: “Bringing CMi2i into the Computershare Group is an exciting development that will enhance our investor relations offering to clients. “The acquisition further demonstrates our commitment to giving companies around the world the edge in the increasingly crucial area of shareholder engagement and ownership intelligence. “CMi2i’s approach to capital markets is very well respected, and their services and systems will complement our wider offering very
Aeromexico Named the Most On-Time Global Airline in 2024:2.1.2025 12:00:00 EET | Press release
Cirium, the world’s most trusted source of aviation analytics, today announced the winners of its 2024 On-Time Performance Review, celebrating airlines and airports that excelled in on-time and operational performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250101214982/en/ Cirium On-Time Performance Review 2024 (Photo: Business Wire) Cirium’s Annual report is the gold standard for global airline and airport performance analytics. An on-time flight is defined as a flight that arrives within 14:59 minutes of the scheduled gate arrival time. Airports measure punctuality as departing flights within 14:59 minutes of their scheduled departure time. Mexico’s Flag Carrier Tops Global Rankings Aeromexico claimed the prestigious title of the most On-Time “Global Airline” in 2024, achieving an impressive On-Time performance rate of 86.70%. Saudia followed closely as the runner-up with 86.35%, while Delta Air Lines secured thir
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 21:00:00 EET | Press release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 13:00:00 EET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 08:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom